These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 20616953)

  • 41. Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management.
    Garcia-Manero G
    Am J Hematol; 2012 Jul; 87(7):692-701. PubMed ID: 22696212
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Myelodysplastic syndromes: 2018 update on diagnosis, risk-stratification and management.
    Montalban-Bravo G; Garcia-Manero G
    Am J Hematol; 2018 Jan; 93(1):129-147. PubMed ID: 29214694
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cedazuridine/decitabine: from preclinical to clinical development in myeloid malignancies.
    Patel AA; Cahill K; Saygin C; Odenike O
    Blood Adv; 2021 Apr; 5(8):2264-2271. PubMed ID: 33904891
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and management.
    Garcia-Manero G
    Am J Hematol; 2014 Jan; 89(1):97-108. PubMed ID: 24464505
    [TBL] [Abstract][Full Text] [Related]  

  • 45. More is better: combination therapies for myelodysplastic syndromes.
    Ornstein MC; Mukherjee S; Sekeres MA
    Best Pract Res Clin Haematol; 2015 Mar; 28(1):22-31. PubMed ID: 25659727
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN.
    Jabbour E; Short NJ; Montalban-Bravo G; Huang X; Bueso-Ramos C; Qiao W; Yang H; Zhao C; Kadia T; Borthakur G; Pemmaraju N; Sasaki K; Estrov Z; Cortes J; Ravandi F; Alvarado Y; Komrokji R; Sekeres MA; Steensma DP; DeZern A; Roboz G; Kantarjian H; Garcia-Manero G
    Blood; 2017 Sep; 130(13):1514-1522. PubMed ID: 28774880
    [TBL] [Abstract][Full Text] [Related]  

  • 47. More is less, less is more, or does it really matter? The curious case of impact of azacitidine administration schedules on outcomes in patients with myelodysplastic syndromes.
    Shallis RM; Zeidan AM
    BMC Hematol; 2018; 18():4. PubMed ID: 29435332
    [TBL] [Abstract][Full Text] [Related]  

  • 48. DNA-hypomethylating agents as epigenetic therapy before and after allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and juvenile myelomonocytic leukemia.
    Flotho C; Sommer S; Lübbert M
    Semin Cancer Biol; 2018 Aug; 51():68-79. PubMed ID: 29129488
    [TBL] [Abstract][Full Text] [Related]  

  • 49. p53-inducible ribonucleotide reductase (p53R2/RRM2B) is a DNA hypomethylation-independent decitabine gene target that correlates with clinical response in myelodysplastic syndrome/acute myelogenous leukemia.
    Link PA; Baer MR; James SR; Jones DA; Karpf AR
    Cancer Res; 2008 Nov; 68(22):9358-66. PubMed ID: 19010910
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Morphological evaluation of dysmyelopoiesis in decitabine-treated patients with myelodysplastic syndromes].
    Dvirnyk VN; Kokhno AV; Glasko EN; Gemdzhian ÉG; Diagileva OA; Platonova TL; Parovichnikova EN
    Ter Arkh; 2013; 85(7):65-71. PubMed ID: 24137949
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Emerging treatment options for patients with high-risk myelodysplastic syndrome.
    Bewersdorf JP; Carraway H; Prebet T
    Ther Adv Hematol; 2020; 11():2040620720955006. PubMed ID: 33240476
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Epigenetic therapy: Research progress of decitabine in the treatment of solid tumors.
    Ye C; Jiang N; Zheng J; Zhang S; Zhang J; Zhou J
    Biochim Biophys Acta Rev Cancer; 2024 Mar; 1879(2):189066. PubMed ID: 38163523
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Gene Expression Profiles Identify Biomarkers of Resistance to Decitabine in Myelodysplastic Syndromes.
    Kim S; Shin DY; Kim D; Oh S; Hong J; Kim I; Kim E
    Cells; 2021 Dec; 10(12):. PubMed ID: 34944006
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS.
    Leone G; Voso MT; Teofili L; Lübbert M
    Clin Immunol; 2003 Oct; 109(1):89-102. PubMed ID: 14585280
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Predicting outcome in higher-risk myelodysplastic syndrome patients treated with azacitidine.
    Bouchla A; Thomopoulos TP; Papageorgiou SG; Apostolopoulou C; Loucari C; Mpazani E; Pappa V
    Epigenomics; 2021 Jul; 13(14):1129-1143. PubMed ID: 34291653
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evolving treatment options of myelodysplastic syndromes.
    Verbeek W; Ganser A
    Ann Hematol; 2001 Sep; 80(9):499-509. PubMed ID: 11669297
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Decitabine.
    Daskalakis M; Blagitko-Dorfs N; Hackanson B
    Recent Results Cancer Res; 2010; 184():131-57. PubMed ID: 20072836
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Myelodysplastic syndromes. Diagnosis and therapeutic strategies].
    Aul C; Giagounidis A; Germing U; Ganser A
    Med Klin (Munich); 2002 Nov; 97(11):666-76. PubMed ID: 12434275
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Treatment options in advanced myelodysplastic syndrome, with emphasis on epigenetic therapy.
    Oki Y; Issa JP
    Int J Hematol; 2007 Nov; 86(4):306-14. PubMed ID: 18055336
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [A preliminary study on the outcome of lower-risk myelodysplastic syndrome by low-dose decitabine].
    Ye L; Ren YL; Xie LL; Luo YW; Lin PP; Zhou XP; Ma LY; Mei C; Xu WL; Wei JY; Jiang HF; Zhang LM; Zeng H; Tong HY
    Zhonghua Xue Ye Xue Za Zhi; 2017 Apr; 38(4):307-312. PubMed ID: 28468092
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.